Real-World Comparison of First-Line Nivolumab plus Ipilimumab versus Pembrolizumab plus Lenvatinib in Advanced Renal Cell Carcinoma (RCC) in a Chinese Population: A Propensity Score-Weighted Analysis (ESMO Asia 2026) - Oct 1, 2026 - Abstract #437P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|
|
Kelvin C. Yan; Hok Ka Chun; Ho Yan Wong
|